Cargando…

Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to

Ruxolitinib is a targeted drug to treat myelofibrosis (MF). Ruxolitinib has significant advantages in spleen reduction and increasing 5-year overall survival (OS), and ruxolitinib-based combinations might provide more benefits than ruxolitinib monotherapy. In this review, we focus on the data of rux...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yujin, Zhu, Shirong, Liu, Weiyi, Ming, Jing, Wang, Xueying, Hu, Xiaomei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237512/
https://www.ncbi.nlm.nih.gov/pubmed/32333155
http://dx.doi.org/10.1007/s00277-020-04028-z